Skip to main content

The Globe and Mail

Cold-FX maker brings some investor relief

The maker of popular cold remedy Cold-FX has reached an agreement to settle two class-action lawsuits with shareholders in an effort to bring a conclusion to three years of devastating news and plunging share values.

Afexa Life Sciences Inc., formerly known as CV Technologies Inc., announced yesterday that it has reached a deal to settle lawsuits that also named its chief science officer, two former directors and the company's former auditors.

The agreement still requires court approval.

Story continues below advertisement

The company said the claims made by shareholders "remain unproven."

"The settlement does not constitute any admission of liability by Afexa or its officers, directors and employees," it said in a statement.

Lawyer Jay Strosberg, whose firm launched the class-action suit on behalf of shareholders in 2007, said the settlement is for $7.1-million, which represents 50 per cent of the approximately $14-million lost by shareholders who bought the stock between the time inflated financial results were released in late 2006 and the company announced its sales would fall in 2007.

"This is a great result for the class members," he said yesterday.

"Any time you can recover a decent size of the total damages without having to litigate and risk losing, it's a great result. So we're very pleased."

He said shareholders will be eligible to participate in the settlement if they bought Afexa stock between Dec. 11, 2006, and March 23, 2007.

The Edmonton-based pharmaceutical firm was one of the fastest-growing small-company stocks on the Toronto Stock Exchange in the mid-2000s, and its ginseng-based herbal cold remedy was touted by hockey personalities such as Don Cherry and Mark Messier. But the company saw its financial health decline after it launched an ambitious U.S. expansion in 2006.

Story continues below advertisement

Afexa reported net revenue of $47-million that year, but it later revealed those numbers were based on the volume of product delivered to U.S. retailers to initially stock their shelves. After sales lagged and inventory was returned, the company revealed in 2007 that it would have to restate its results for 2006 and the first quarter of 2007.

The company said it underestimated the amount of product that would be returned when it booked its sales for the periods.

Afexa reduced its 2006 profit to $639,000 from $4.1-million, and changed its earnings for the first quarter of 2007 to a loss of $3.6-million from an original loss of $1.6-million.

The company's shares, which hit a high of $4.46 in October, 2006, dropped quickly and have never recovered their former glory.

CV changed its name to Afexa in April this year as part of a rebranding strategy.

Afexa Life Sciences (FXA)

Story continues below advertisement

Close: 56¢, up 5¢

Report an error Licensing Options
About the Author
Real Estate Reporter

Janet McFarland is the real estate reporter for The Globe and Mail’s Report on Business, with a focus on residential real estate trends. She joined Report on Business in 1995, and has specialized in reporting on corporate governance, executive compensation, pension policy, business law, securities regulation and enforcement of white-collar crime. More

Comments are closed

We have closed comments on this story for legal reasons. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.

Combined Shape Created with Sketch.

Combined Shape Created with Sketch.

Thank you!

You are now subscribed to the newsletter at

You can unsubscribe from this newsletter or Globe promotions at any time by clicking the link at the bottom of the newsletter, or by emailing us at privacy@globeandmail.com.